Both the companies will discover, develop and commercialize synthetic siRNA directed towards an undisclosed target for the treatment of glaucoma.
Once Sylentis exercises this option, Alnylam will be entitled to receive upfront and milestone payments, as well as royalties on sales of products covered by the licensing agreement.
The financial details of the deal have not been disclosed.
Alnylam senior vice president and chief business officer Laurence Reid said the deal with Sylentis reflects progress with their InterfeRx program and would create value by leveraging their intellectual property portfolio.